Сергей Пузанов – Multiple Sclerosis. Everything you need to know (страница 12)

Ultimately, a spinal tap is an incredibly informative analysis, but managing it comes with significant operational friction. The main hurdle isn't the test itself; it's how fast and carefully the courier hauls the sample to the lab matrix. If, after a random MRI throws up burning spots, your lumbar puncture returns a Type 1 synthesis profile (clean, no bands), you experience zero clinical symptoms, and a neurologist says, "Here are some interferons, they will help," know this: a second independent spinal tap will drastically cut down the probability of a "missed" diagnosis caused by a spoiled sample. Yes, it is painful, and yes, it is unpleasant—but is it worse than spending the rest of your life being treated for a disease you don't even have? Still, you cannot overlook the fact that you might sit among the 5% of people whose genuine MS operates along a polyclonal track. That said, as you can see from how the analysis works, generating a fake Type 2 profile (visible bands) without a massive laboratory blunder is practically impossible. But don't assume a Type 2 synthesis profile automatically means MS either; OCBs are not an exclusive hallmark of multiple sclerosis—they show up in other inflammatory CNS conditions as well.

In the context of multiple sclerosis, the metrics that matter are Type 1 and Type 2 synthesis profiles. Type 1 is completely normal; Type 2 is oligoclonal and highly characteristic of MS. In an effort to measure how well my fellow comrades in misfortune comprehend their lab results, I ran a poll: "Which spinal tap result belongs to a perfectly healthy person?" I offered three options: Type 1 synthesis, Type 2 synthesis, and "absence of synthesis." Spoiler alert: the last option doesn't exist in nature—a healthy profile is always labeled Type 1. Yet, 40% of the hundreds of patients who voted selected "absence of synthesis"—likely because they were convinced that Type 1 and Type 2 were both variants of an MS diagnosis, exactly as their neurologists told them. Less than half of Russian MS patients understand that a Type 1 synthesis profile means a negative test result.

Another poll asking, "Which synthesis type did your lumbar puncture reveal?" yielded these numbers: Type 2 synthesis — 30%; Type 1 synthesis — 20%; "never had a spinal tap" — 39%; other — 11%. Since Type 3 synthesis (Okonclonal bands showing up identically in both the CSF and blood serum) occurs in only 5 to 7% of genuine MS cases and is exceptionally rare in the wild, I frankly don't know what those who selected "other" had in mind. Between Type 1 and Type 2, the answers split 3:2, mapping to 60% and 40%, which explicitly proves that a massive slice of the polled population is actively treating a non-existent disease. It’s tough to calculate how the numbers would split in the "never had a tap" bracket, but I suspect the tilt toward Type 1 would be even more severe. It’s no surprise that a follow-up poll showed 65% of patients believe the spinal tap is non-informative—they don't know why; it’s simply what their doctors told them.

By the way, there is a myth floating around the internet that a spinal tap will only reveal a Type 2 profile several years after the disease starts—this is flat-out wrong. Once the first rogue T-cell breaches the brain, all it takes is a few chemical signals to draw B-cells into the hotspot. Once inside the brain tissue, B-cells activate and multiply; plasma cells debut continuously, and antibody production kicks off within the very first months of the disease. Within 3 to 6 months of the initial BBB breach, the volume of printed antibodies is high enough to construct visible oligoclonal bands on a gel matrix, yet actual clinical symptoms are still miles away—they typically manifest only 5 to 10 years after the demyelination process begins. Even if you are lucky enough to land on an MRI scanner before B-cells scale up their antibody factories, the budding hotspots will look like microscopic pinpricks—hardly enough for even an exceptionally sharp radiologist to confidently flag.

If someone were to open a specialized center in Russia where the CSF sample could be dropped onto a gradient matrix immediately after extraction and filtering, the accuracy of tracking oligoclonal bands would approach absolute perfection. In other words, to fix this diagnostic vulnerability, you simply need to haul the patients to the laboratory matrix, rather than hauling the biological material across town. The idea is simple, but no one is in any hurry to execute it. Why? I think it’s because the entire multiple sclerosis treatment market has long stabilized around MRI hotspots, and nobody wants to rock the boat. On top of that, it seems very few neurologists have ever bothered to look under the hood of the analysis to understand why it can return a "non-informative" result.

On Courses and the "Continuum" of Multiple Sclerosis

If you carefully read the section of the first chapter dedicated to the pathogenesis of multiple sclerosis, you should have realized that this disease has existed for as many years as humanity itself. The randomized assembly of lymphocyte receptors driven by V(D)J recombination emerged long before fish first crawled out of the water—at least 500 million years ago. Autoimmune glitches were bound to appear alongside this evolutionary innovation. The EBV virus, considered one of the chief triggers for MS today, is no newcomer either; it emerged about 12 million years ago. Honestly, it is hard to even imagine how ancient healers explained the symptoms of multiple sclerosis—likely attributing them to curses, witchcraft, and the wrath of angry gods. But that is all in the distant past: let’s fast forward to 1868, when Jean-Martin Charcot first described multiple sclerosis.

Charcot—who, by the way, was the first professor of neurology in history—saw MS patients far too late, when the symptoms of the disease could no longer be missed. This was roughly a century before the arrival of MRI scanners, so he could only see demyelination lesions during autopsies. All that was left for him was to observe the living sick. What he saw was a prolonged, monotonous, merciless decline—patients simply got worse and worse. He mapped out the chief "hallmarks" of the disease but could do absolutely nothing for the patients. Charcot didn't understand what was tearing his patients' brains apart, but he had no doubt that the disease was progressive and incurable—his observations confirmed that once multiple sclerosis starts, movement down this terrifying road goes in only one direction.

Charcot’s rigid concept began cracking at the seams by the 1920s. The disease was being caught at earlier stages, and doctors discovered to their amazement that after furious flare-ups, symptoms could completely vanish. Neurology plunged into a century-long abyss of terminological chaos. German neurologist Otfrid Foerster and his colleagues were the first to speak of the "intermittent" (interrupted) nature of the ailment, but no clear label was stamped on this phenomenon. By the mid-20th century, physicians began competing in linguistic creativity, racing to pack the unpredictability of MS into resonant tags. Medical charts were flooded with dozens of diagnoses: from "Marburg's acute malignant sclerosis," where a person burned out in months, to "McAlpine's benign sclerosis," where a patient went decades without developing a disability. Even in 1983, when Charles Poser's committee tried to bring order to the chaos, they only managed to standardize the diagnostic criteria, splitting MS into "definite" and "probable." The problem of disease courses remained untouched; scientists in the US flat-out didn't understand their colleagues in Europe. Pharmacology stalled: it was impossible to run clean clinical trials of drugs while researchers were still arguing over the names of an enemy that swapped masks at different stages of its life.

This linguistic schism dragged on until 1996, when the "International Advisory Committee on Clinical Trials of MS," spearheaded by Professor Fred Lublin, forced the world to speak a single language. Lublin took the path of hard-nosed pragmatism: his team blasted detailed questionnaires to 186 of the top neurologists across 18 countries. Aggregating and digitizing the opinions of the planet's brightest minds, the Committee hammered out a consensus that instantly buried dozens of subjective terms from the past. The world of multiple sclerosis was split into four isolated rooms. The first was assigned to relapsing-remitting multiple sclerosis (RRMS), with its distinct flare-ups and remissions. The second went to secondary-progressive multiple sclerosis (SPMS), where after a period of attacks, the disease launched a slow, uninterrupted advance. The third was handed to primary-progressive multiple sclerosis (PPMS), where decline marched from day one without any rollbacks. The fourth and rarest room was left for progressive-relapsing MS (PRMS). Fred Lublin brought an end to the global chaos: from that moment on, any doctor in Tokyo, Paris, or New York opened a chart and saw the exact same letters. Pharmaceutical companies received clear rules of the game and were finally able to launch targeted drug trials. No one suspected that this neat, orderly grid was nothing more than an illusion.